Fulgent Genetics, Inc. reports developments across a laboratory services business and a therapeutic development business. Its laboratory operations provide technical laboratory and genetic testing services, with professional interpretation of results by licensed physicians. Its therapeutic development work focuses on cancer drug candidates using a nanoencapsulation and targeted therapy platform designed for new and existing oncology drugs.
Recurring company news includes operating and financial results, revenue guidance, stock repurchase activity, laboratory-services partnerships, and precision medicine testing initiatives. Clinical updates also cover oncology programs such as FID-007 and FID-022, including disclosures related to head and neck cancer research and presentations at oncology meetings.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.